Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]
Lung Cancer. 2024 Nov:197:108000.
doi: 10.1016/j.lungcan.2024.108000.
Epub 2024 Nov 2.
1 Department of Hematology and Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, United States. Electronic address: jessica.bauman@fccc.edu.
2 Medical Oncology and Hematology, Princess Margaret Cancer Centre, 200 Elizabeth Street, Toronto, ON M5G 0A3, Canada. Electronic address: geoffrey.liu@uhn.ca.
3 Thoracic Oncology, Memorial Sloan Kettering Cancer Center, 225 Summit Avenue, Montvale, NJ 07645, United States. Electronic address: preeshai@mskcc.org.
4 Thoracic Oncology, Georgetown University, 37th and O Streets NW, Washington, DC 20057, United States. Electronic address: stephen.liu@gunet.georgetown.edu.
5 Department of Medicine, BC Cancer - Vancouver, 2775 Laurel Street, Vancouver, BC V5Z 1M9, Canada. Electronic address: bmelosky@bccancer.bc.ca.
6 HTA Value and Evidence, Oncology, Pfizer, 66 Hudson Boulevard, New York, NY 10001, United States. Electronic address: devin.abrahami@pfizer.com.
7 Biostatistics, Pfizer, 66 Hudson Boulevard, New York, NY 10001, United States. Electronic address: benjamin.li@pfizer.com.
8 Global Medical Affairs, Pfizer, 243 Mesogeion Avenue, Neo Psychiko, Athens 154 51, Greece. Electronic address: despina.thomaidou@pfizer.com.
9 US Medical Affairs, Pfizer, 66 Hudson Boulevard, New York, NY 10001, United States. Electronic address: kirsten.duncan@pfizer.com.
10 US Medical Affairs, Pfizer, 66 Hudson Boulevard, New York, NY 10001, United States. Electronic address: stan.krulewicz@pfizer.com.
12 Center for Thoracic Cancers, Department of Medicine, Cancer Center, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States. Electronic address: jjlin1@mgb.org.